Chemical Property of 4-{[(7r)-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxy-N-(1-Methylpiperidin-4-Yl)benzamide
Chemical Property:
- PKA:14.09±0.20(Predicted)
- PSA：102.93000
- Density:1.28 g/cm3
- LogP:4.08860
- Storage Temp.:Keep in dark place,Sealed in dry,Store in freezer, under -20°C
- Solubility.:Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml)
- XLogP3:3.7
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:8
- Rotatable Bond Count:7
- Exact Mass:521.31143813
- Heavy Atom Count:38
- Complexity:816
- Purity/Quality:
-
99%, *data from raw suppliers
BI2536 *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C
- Isomeric SMILES:CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C
- Recent ClinicalTrials:BI 2536 Second Line Monotherapy in SCLC
- Recent EU Clinical Trials:Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EORTC Network of Core Institutions (NOCI)
-
Description
BI 2536 (755038-02-9) was originally reported as a potent (IC50’s Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM)1?and selective2?Polo-like kinase inhibitor?that caused mitotic arrest and apoptosis induction in various human cancer cell lines.1?It was later found to be a potent inhibitor (IC50?= 100nM) of BET family member BRD4 and able to potently suppress c-Myc expression in MM.1S multiple myeloma cells.3?BI 2536 destabilizes N-Myc by inhibiting the deactivation of the ubiquitin E3 ligase Fbw7 by Plk1.4
-
Uses
BI 2536 is a PLK1 inhibitor, inducing apoptosis together with micro-tubule-destabilizing drugs in preclinical rhabdomyosarcoma models. Anti-cancer and potent PLK1 inhibitor.
